N07.B
Hereditary nephropathy, not elsewhere classified with APOL1-mediated kidney disease [AMKD]
Clinical Classification Guidelines
Inclusion Terms
- AMKD (with glomerulonephritis)
- AMKD (with glomerulosclerosis)
Medical Intelligence & Overview
Hereditary nephropathy with APOL1-mediated kidney disease, classified under ICD-10 code N07.B, is a genetic kidney disorder characterized by progressive kidney damage. This condition is associated with specific genetic variants in the APOL1 gene, which are more common in individuals of certain ancestries, especially those of African descent. The disease often manifests with signs of kidney dysfunction and can lead to chronic kidney disease or end-stage renal disease if not properly managed. Additionally, this form of nephropathy may be associated with glomerulonephritis or glomerulosclerosis, contributing to its complexity and severity.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations in the APOL1 gene, primarily found in individuals of African ancestry. Presence of specific APOL1 risk alleles that increase susceptibility to kidney damage. Additional genetic factors that may influence disease progression and severity. Environmental factors or comorbid conditions that might exacerbate kidney injury, such as hypertension or diabetes, although these are not primary causes.
Key Symptoms: Persistent swelling or edema, especially in the legs, ankles, and around the eyes. Foamy urine indicating proteinuria. Fatigue and weakness due to reduced kidney function. High blood pressure, often difficult to control. Changes in urination patterns, such as increased frequency or decreased volume. Unintentional weight loss and decreased appetite in advanced stages. Potential development of symptoms related to glomerulonephritis or glomerulosclerosis, including blood in the urine or reduced kidney function.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of hereditary nephropathy related to APOL1 involves a combination of clinical assessment, laboratory tests, and genetic analysis. Healthcare providers may perform the following to confirm the condition: - Urinalysis to detect proteinuria or hematuria. - Blood tests to evaluate kidney function, including serum creatinine and estimated glomerular filtration rate (eGFR). - Kidney imaging studies such as ultrasound to assess kidney size and structure. - Genetic testing to identify APOL1 risk alleles, especially in patients with a family history of kidney disease or from high-risk populations. - Kidney biopsy in some cases to evaluate histopathological features like glomerulonephritis or glomerulosclerosis.
Treatment Protocols: While there is no specific cure for hereditary nephropathy with APOL1-mediated kidney disease, management focuses on slowing disease progression and addressing symptoms: - Controlling blood pressure with antihypertensive medications. - Reducing protein intake to lessen strain on the kidneys. - Managing complications such as anemia and electrolyte imbalances. - Using medications to reduce proteinuria, such as ACE inhibitors or ARBs. - Monitoring kidney function regularly to detect early signs of deterioration. - Preparing for renal replacement therapy, such as dialysis or transplantation, in advanced cases. - Genetic counseling for affected individuals and families to understand inheritance patterns and risks.
Clinical Advice & FAQs
Billing Guidance
Is N07.B a billable ICD-10 code?
Yes, N07.B is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report N07.B?
Clinical documentation must specify the nature of Hereditary nephropathy, not elsewhere classified with APOL1-mediated kidney disease [AMKD] and any associated comorbidities for accurate reporting.
Cite this Clinical Reference